{"id":47464,"date":"2025-02-27T08:18:14","date_gmt":"2025-02-27T08:18:14","guid":{"rendered":"https:\/\/my.legal500.com\/developments\/?post_type=press_releases&#038;p=47464"},"modified":"2025-02-27T08:18:57","modified_gmt":"2025-02-27T08:18:57","slug":"ab2-bio-signs-option-and-licensing-agreement-with-nippon-shinyaku","status":"publish","type":"press_releases","link":"https:\/\/my.legal500.com\/developments\/press-releases\/ab2-bio-signs-option-and-licensing-agreement-with-nippon-shinyaku\/","title":{"rendered":"AB2 Bio signs option and licensing agreement with Nippon Shinyaku"},"content":{"rendered":"<p dir=\"auto\"><strong>Niederer Kraft Frey advised AB2 Bio Ltd, a Lausanne, Switzerland based biotechnology company developing innovative therapies for the treatment of severe systemic hyperinflammatory diseases and conditions driven by IL-18,<\/strong><!--more--><span style=\"font-size: 1rem\">on Swiss law matters in connection with the entry into an option and licensing agreement with Nippon Shinyaku Co. Ltd., a leading Japanese pharmaceutical company.<\/span><\/p>\n<p dir=\"auto\">Under the terms of the agreement, Nippon Shinyaku received an option to acquire exclusive U.S. rights to commercialize Tadekinig alfa to treat Primary Monogenic IL-18 driven Hyperinflammatory Syndrome, a rare and potentially life-threatening pediatric disease that, if left untreated, may rapidly lead to multiple-organ failure and death. AB2 Bio will continue to prepare for filing for U.S. Biologics License Application (BLA) approval for Tadekinig alfa in the indication.<\/p>\n<p dir=\"auto\">AB2 Bio receives early payments of up to USD 36 million (including an initial payment of USD 6 million upon closing) and would be eligible for development milestone payments of up to USD 150 million and commercial milestone and royalty payments of up to USD 500 million.<\/p>\n<p dir=\"auto\">The NKF team was led by Corporate\/M&amp;A partner Jacques Bonvin, working with partner Andrea Wuerzner (Corporate\/M&amp;A) and associate Boris Catzeflis (Corporate\/M&amp;A and Technology).<\/p>\n<hr \/>\n<p dir=\"auto\">\n","protected":false},"featured_media":0,"template":"","class_list":["post-47464","press_releases","type-press_releases","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/my.legal500.com\/developments\/wp-json\/wp\/v2\/press_releases\/47464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/my.legal500.com\/developments\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/my.legal500.com\/developments\/wp-json\/wp\/v2\/types\/press_releases"}],"wp:attachment":[{"href":"https:\/\/my.legal500.com\/developments\/wp-json\/wp\/v2\/media?parent=47464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}